Once-Weekly Cardiac Support for Cats Product Description Fight back with Felycin-CA1 (sirolimus delayed-release tablets). The first FDA conditionally approved, once-weekly drug for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy, or HCM. A silent killer of cats that affects one of every seven cats. Finally, screening cats to diagnose this disease early will help put an end to owners feeling powerless. The solution of Felycin-CA1 is the only disease-modifying drug for cats with HCM. Benefits Proven safe with a reasonable expectation of effectiveness; Felycin-CA1 is the first and only disease-modifying drug for cats with HCM. Felycin-CA1 is administered once-weekly and is formulated specifically for cats in small tablet sizes for easy administration. Felycin-CA1 is an affordable treatment option for cat owners that may prevent and delay progressive LV hypertrophy that affects 1 in 7 cats. A conditionally approved drug is a designated by the FDA that is given when a product has been proven safe with a reasonable expectation of effectiveness based on the studies performed. This designation is often used by the FDA when there is an established need in disease states for which there is no other treatment option while the drug manufacturer continues to perform all required testing in larger cat populations. Felycin-CA1 is a prescription drug to be prescribed by a licensed veterinarian after a confirmed HCM diagnosis. Felycin-CA1 should not be used in cats with diabetes mellitus. Do not administer in cats with pre-existing liver disease. Variants 0.4 mg tablet strength 1.2 mg tablet strength 2.4 mg tablet strength Active Ingredient Sirolimus (rapamycin) How to Use Directions Felycin-CA1 (sirolimus delayed-release tablets) should be given orally daily as directed by your veterinarian with or without food. Recommended Dosage Chart Body Weight (kg) 0.4 mg 1.2 mg 2.4 mg 2.5 – 3.2 2 0 0 3.3 – 4.8 0 1 0 4.9 – 6.4 1 1 0 6.5 – 9.6 0 1 1 > 9.6 0 1 1 Disclaimer: This dosage information is provided by the manufacturer. Always consult your veterinarian before administering or adjusting any supplement for your pet. Dosage and Administration Instructions Administer FELYCIN®-CA1 at a target dosage of 0.3 mg/kg (0.14 mg/lb) orally once weekly. Approximate pounds (lbs) equivalents are provided for convenience only. Always consult your veterinarian for the most accurate dosing, and to ensure proper use of this medication. FELYCIN®-CA1 should be swallowed whole and not chewed. Do not split or crush tablets. FELYCIN®-CA1 should be administered in conjunction with a meal. Additional Information Precautions Not for diabetic cats: Do not use in cats with diabetes mellitus, and discontinue immediately if diabetes is diagnosed. Avoid liver disease cases: Do not administer to cats with existing liver disease due to increased metabolic risk and enzyme elevation. Monitor liver enzymes: Check ALT and AST before treatment and repeat testing one to two months after starting therapy. Discontinue for high enzymes: Stop treatment if ALT or AST exceeds two times the upper limit of normal values. Use caution with drug interactions: Avoid concurrent use with CYP3A4 or P-glycoprotein inhibitors like azoles or cyclosporine. Avoid use in intact animals: Effectiveness has not been evaluated in sexually intact cats and should not be used in breeding animals. Use caution with MDR1 mutation: Cats with MDR1 gene variants may have altered drug transport requiring extra veterinary oversight. Possible Side Effects The most frequently observed adverse reactions in cats treated with FELYCIN®-CA1 were cardiovascular in nature, relating to the progression of HCM, and included arrhythmia, congestive heart failure, syncope, and pericardial effusion. Other adverse reactions observed were lethargy, vomiting, diarrhea, and inappetence. Storage Information Store at 68-77°F (20-25°C). Excursions permitted between 59-86°F (15-30°C). Shipping & Return We offer ground, express, priority, and international delivery; see our shipping policy for details. For return instructions or product concerns, please refer to our detailed refund policy. Prescription items are NON-RETURNABLE and NON-REFUNDABLE. Frequently Asked Questions Q1: Why is Felycin-CA1 considered a breakthrough treatment for cats with HCM? Ans: Felycin-CA1 is the first and only disease-modifying therapy proven safe with a reasonable expectation of effectiveness for managing feline hypertrophic cardiomyopathy. It offers veterinarians a new way to address the underlying condition rather than only treating symptoms. Q2: How often do I need to give Felycin-CA1 to my cat? Ans: Felycin-CA1 is given once weekly and is made specifically for cats using small tablet sizes that make dosing easier for pet owners. This formulation supports simple and stress-free administration during long-term heart care. Q3: How can Felycin-CA1 help protect my cat’s heart long term? Ans: Felycin-CA1 is an affordable treatment option that may help prevent and delay progressive left ventricular hypertrophy, a condition affecting roughly one in seven cats. Its once-weekly dosing supports early intervention for better long-term cardiac health. Q4: What does it mean that Felycin-CA1 is conditionally approved by the FDA? Ans: Conditional approval means the FDA has determined the medication is proven safe with a reasonable expectation of effectiveness. This designation is used when no other treatment exists, allowing access while the manufacturer completes required studies in larger cat populations. Q5: When can my cat be prescribed Felycin-CA1? Ans: Felycin-CA1 can only be prescribed by a licensed veterinarian after confirming hypertrophic cardiomyopathy. It must not be used in cats with diabetes mellitus or those with pre-existing liver disease, as these conditions increase risk during treatment. Q6: How should I give Felycin-CA1 to my cat? Ans: Felycin-CA1 should be given orally exactly as instructed by your veterinarian, with or without food. Always follow the dosing schedule provided by your vet to ensure proper use and consistent therapeutic benefit for your cat. Q7: What is Felycin-CA1 used for in cats? Ans: Felycin-CA1 is used to manage ventricular hypertrophy in cats diagnosed with subclinical hypertrophic cardiomyopathy. It modifies disease progression by reducing heart muscle thickening when used once weekly as directed. Q8: How long does my cat need to stay on Felycin-CA1? Ans: Cats with subclinical HCM typically remain on Felycin-CA1 long term because the treatment works to slow progressive cardiac thickening over time. Continued weekly dosing is recommended unless a veterinarian advises changes. Q9: Can Felycin-CA1 be given with other medications? Ans: Certain medications like azoles, amiodarone, cyclosporine, and calcium channel blockers may affect sirolimus metabolism. Veterinarians must evaluate drug interactions before combining therapies to ensure safe use. Q10: What signs should I watch for while my cat is taking Felycin-CA1? Ans: Cats should be monitored for vomiting, diarrhea, reduced appetite, lethargy, arrhythmias, or breathing concerns. Any sudden collapse or worsening clinical signs requires immediate veterinary evaluation during therapy. Q11: How soon can improvements be seen with Felycin-CA1? Ans: Clinical studies show reductions in maximal left ventricular wall thickness after 180 days of weekly dosing. Regular veterinary checkups and echocardiograms help assess progress during treatment.
